Figure 1 : Macular SD-OCT images (Spectralis) before and after
intravitreal bevacizumab.

(A) Significant CME with subretinal subfoveal fluid, BCVA 20/160, CFT of
738 μm/12.99 mm2 prior to treatment. (B) Reduced CME with resolution
of subretinal fluid, BCVA 20/70, CFT of 319 μm/9.27 mm2 10 weeks after
bevacizumab injection.

Todorich et al.Journal of Eye and Ophthalmology  2014 1:3DOI : 10.7243/2055-2408-1-3